Curculigoside attenuates human umbilical vein endothelial cell injury induced by H2O2.
OBJECTIVE
Vessel endothelium injury caused by reactive oxygen species (ROS) including H(2)O(2) plays a critical role in the pathogenesis of cardiovascular disorders. Therefore, agents or antioxidants that can inhibit production of ROS has highly clinical values in cardiovascular therapy. Curculigoside is the major bioactive compounds present in Curculigo orchioides, and possess potent antioxidant properties against oxidative stress insults through undefined mechanism(s). The present study was designed to test the hypothesis that curculigoside can inhibit H(2)O(2)-induced injury in human umbilical vein endothelial cells.


METHODS
Human umbilical vein endothelial cells (HUVECs) were treated with curculigoside in the presence/absence of hydrogen peroxide (H(2)O(2)). The protective effects of curculigoside OP-D against H(2)O(2) were evaluated.


RESULTS
HUVECs incubated with 400 μM H(2)O(2) had significantly decreased the viability of endothelial cells, which was accompanied with apparent cells apoptosis, the activation of caspase-3 and the upregulation of p53 mRNA expression. In addition, H(2)O(2) treatment induced a marked increase of MDA, LDH content and in intracellular ROS, decreased the content of nitric oxide (NO) and GSH-Px activities in endothelial cells. However, pretreatment with 0.5.5,10 μM curculigoside resulted in a significant recovery from H(2)O(2)-induced cell apoptosis. Also, it decreased other H(2)O(2)-induced damages in a concentration-dependent manner. Furthermore, pretreatment with curculigoside decreased the activity of caspase-3 and p53 mRNA expression, which was known to play a key role in H(2)O(2)-induced cell apoptosis.


CONCLUSIONS
The present study shows that curculigoside can protect endothelial cells against oxidative injury induced by H(2)O(2), suggesting that this compound may constitute a promising intervention against cardiovascular disorders.
Wang
Yun Kai
YK
Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China. cloudopen002@yahoo.com.cn
Hong
Ya Jun
YJ
Wei
Mao
M
Wu
Ye
Y
Huang
Zhao Quan
ZQ
Chen
Rui Zhen
RZ
Chen
Hao Zhu
HZ
D000975:Antioxidants / Q000302:isolation & purification / Q000494:pharmacology*; D001565:Benzoates / Q000302:isolation & purification / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D031408:Curculigo / Q000737:chemistry; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D017382:Reactive Oxygen Species / Q000378:metabolism; D027343:Rhizome / Q000737:chemistry; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D000975:Antioxidants; D001565:Benzoates; D005960:Glucosides; D017382:Reactive Oxygen Species; D009569:Nitric Oxide; C477170:curculigoside; D006861:Hydrogen Peroxide